Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

polycythemia - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

polycythemia

MONDO:0005571

Also known as:erythrocythemiapolycythemia (disease)

Find Clinical TrialsTrials

Overview

Abnormally high mass or concentration of red blood cells in the blood, either due to an increase in erythropoiesis or a decrease in plasma volume.

Treatments2 FDA approved

Clinical Trials90 registered · 47 recruiting

Diagnosis

Biomarker and diagnostic research for polycythemia has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for polycythemia, including MOMELOTINIB (OJJAARA, approved 2023) and FEDRATINIB HYDROCHLORIDE (INREBIC, approved 2019).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

90 clinical trials registered, 47 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 4 PHASE4, 14 PHASE3, 28 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05031897](https://clinicaltrials.gov/study/NCT05031897)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 3:29 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:98427

GARD

Genetic and Rare Diseases Info Center

GARD:19466

Questions for Your Care Team

→What are the benefits and potential side effects of OJJAARA for managing polycythemia?
→Are any of the 90 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	78	26%
Patient case studies	54	18%
Disease patterns and progression	48	16%
Laboratory research	41	14%
Clinical study results	38	13%
Testing and diagnosis research	22	7%
Other research	9	3%
New treatment approaches	7	2%

polycythemia

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications